Table 2.

Changes of the Study Variables in the 3 Groups During the 12 Weeks

	Semaglutide Baseline n = 30	12 Weeks n = 28	P	Dulaglutide Baseline n = 30	12 Weeks n = 28	P	Metformin Baseline n = 20	12 Weeks n = 18	P
BMI (Kg/m2)	34.3 ± 5	33.8 ± 4	ns	36.5 ± 6	34 ± 5	ns	33.5 ± 6	32.1 ± 4	ns
HbA1c (%)	7.3 ± 1.2	6.9 ± 1.2	ns	8.2 ± 1.2	7.7 ± 1.1	ns	5.8 ± 0.6	5.9 ± 0.9	ns
SBP (mmHg)	132 ± 13	131 ± 14	ns	127 ± 18	126 ± 16	ns	123 ± 15	127 ± 17	ns
DBP(mmHg)	79.5 ± 8	81 ± 8	ns	76.8 ± 13	78 ± 9	ns	77.5 ± 9	76 ± 10	ns
HR (bpm)	79 ± 10	81 ± 11	ns	83 ± 13	79 ± 15	ns	75 ± 13	77 ± 16	ns
LDL (mg/dl)	99 ± 41	78 ± 30	ns	87 ± 33	78 ± 41	ns	116 ± 36	89 ± 17	< 0.05
HDL(mg/dl)	45 ± 16	44 ± 16	ns	43 ± 15	42 ± 13	ns	47 ± 11	55 ± 23	ns
EAT (mm)	9.5 ± 2.6	7.5 ± 2	< 0.01	9.3 ± 2.2	7.7 ± 2.2	< 0.01	7.1 ± 2.1	7.1 ± 2.2	ns

Table 2 shows the cumulative effects of semaglutide and dulaglutide regardless of the medication dosage. Data are expressed as mean ± SD.

Abbreviations: BMI, body mass index; DBP, diastolic blood pressure; EAT, epicardial adipose tissue; HbA1c, hemoglobin A1c; HDL, high density lipoprotein cholesterol; HR, heart rate; LDL, low density lipoprotein cholesterol; SBP, systolic blood pressure.